MX2017010159A - Vector que expresa conjuntamente vacunas y moléculas coestimuladoras. - Google Patents
Vector que expresa conjuntamente vacunas y moléculas coestimuladoras.Info
- Publication number
- MX2017010159A MX2017010159A MX2017010159A MX2017010159A MX2017010159A MX 2017010159 A MX2017010159 A MX 2017010159A MX 2017010159 A MX2017010159 A MX 2017010159A MX 2017010159 A MX2017010159 A MX 2017010159A MX 2017010159 A MX2017010159 A MX 2017010159A
- Authority
- MX
- Mexico
- Prior art keywords
- vector
- costimulatory molecules
- expressing
- expressing vaccine
- cell
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000000139 costimulatory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000020385 T cell costimulation Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
Abstract
Se proporcionan aquí composiciones y métodos para expresar en conjunto una proteína de vacuna secretable (tal como gp96-Ig) y moléculas coestimuladoras de células T de un solo vector, entre otros. También se proporcionan materiales y métodos para usar la vacunación con gp96-Ig y coestimulación de células T para tratar una afección clínica (por ejemplo, cáncer) en un sujeto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562113153P | 2015-02-06 | 2015-02-06 | |
US201562174942P | 2015-06-12 | 2015-06-12 | |
PCT/US2016/016682 WO2016127015A1 (en) | 2015-02-06 | 2016-02-05 | Vector co-expressing vaccine and costimulatory molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017010159A true MX2017010159A (es) | 2017-12-18 |
Family
ID=56564722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010159A MX2017010159A (es) | 2015-02-06 | 2016-02-05 | Vector que expresa conjuntamente vacunas y moléculas coestimuladoras. |
Country Status (16)
Country | Link |
---|---|
US (4) | US10046047B2 (es) |
EP (1) | EP3253876B1 (es) |
JP (1) | JP6744318B2 (es) |
KR (1) | KR20170109582A (es) |
CN (1) | CN107208099B (es) |
AU (1) | AU2016215175B2 (es) |
BR (1) | BR112017016681A2 (es) |
CA (1) | CA2975191C (es) |
DK (1) | DK3253876T3 (es) |
ES (1) | ES2845727T3 (es) |
HK (1) | HK1247960A1 (es) |
IL (1) | IL253423B (es) |
MX (1) | MX2017010159A (es) |
RU (1) | RU2714157C2 (es) |
SG (1) | SG11201705844SA (es) |
WO (1) | WO2016127015A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017016681A2 (pt) * | 2015-02-06 | 2018-04-10 | Heat Biologics Inc | vetor de coexpressão de vacina e moléculas coestimulatórias |
CN107708725A (zh) * | 2015-04-02 | 2018-02-16 | 坎库雷有限公司 | 用于引发免疫应答的剂和组合物 |
CA2999280A1 (en) | 2015-10-01 | 2017-04-06 | Heat Biologics, Inc. | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
KR20190059304A (ko) * | 2016-09-26 | 2019-05-30 | 어드밴테이진, 인크. | Tim-3 상승을 치료하는 방법 |
WO2018071405A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
JP7128195B2 (ja) | 2017-02-27 | 2022-08-30 | シャタック ラボ,インコーポレイテッド | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
US11267856B2 (en) * | 2017-02-27 | 2022-03-08 | Shattuck Labs, Inc. | CSF1R-CD40L chimeric proteins |
WO2018157163A1 (en) * | 2017-02-27 | 2018-08-30 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
WO2018187260A1 (en) * | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
CA3083481A1 (en) * | 2017-11-27 | 2019-05-31 | Heat Biologics, Inc. | Gp96-based cancer therapy |
EP3720450A4 (en) * | 2017-12-04 | 2021-07-28 | Heat Biologics, Inc. | Manufacture of cell-based vaccines |
US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
CN112888706A (zh) * | 2018-08-29 | 2021-06-01 | 沙塔克实验室有限公司 | 包含基于tim-3的嵌合蛋白的组合疗法 |
MX2021002294A (es) * | 2018-08-29 | 2021-05-27 | Shattuck Labs Inc | Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1. |
EP3860647A4 (en) * | 2018-10-01 | 2022-10-19 | Heat Biologics, Inc. | CELL-BASED POLYTHERAPIES |
EP3883955A1 (en) * | 2018-11-19 | 2021-09-29 | Board of Regents, The University of Texas System | A modular, polycistronic vector for car and tcr transduction |
WO2021178416A1 (en) * | 2020-03-02 | 2021-09-10 | Heat Biologics, Inc. | Immune-mediated coronavirus treatments |
CN118201636A (zh) * | 2021-10-26 | 2024-06-14 | 萨摩亚商柏沛生医股份有限公司 | 抗癌症及感染性疾病的组合疗法 |
Family Cites Families (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US5217891A (en) | 1987-07-28 | 1993-06-08 | Chiron Corporation | DNA constructs containing a kluyveromyces α factor leader sequence for directing secretion of heterologous polypeptides |
EP0419569B1 (en) | 1988-06-15 | 1995-09-06 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
WO1990002564A1 (en) | 1988-09-12 | 1990-03-22 | Codon | Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi |
US5232833A (en) | 1988-09-14 | 1993-08-03 | Stressgen Biotechnologies Corporation | Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants |
JPH04503309A (ja) | 1989-07-28 | 1992-06-18 | アメリカ合衆国 | 効果的な方向性遺伝子クローニング系 |
GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
US5348945A (en) | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
US5188964A (en) | 1990-04-12 | 1993-02-23 | Board Of Regents, The University Of Texas System | Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination |
WO1992008488A1 (en) | 1990-11-08 | 1992-05-29 | University College London | Mycobacterium as adjuvant for antigens |
GB9016315D0 (en) | 1990-07-25 | 1990-09-12 | Burnie James P | Medicaments |
GB9024320D0 (en) | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
GB2251186A (en) | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
US5177942A (en) | 1991-08-15 | 1993-01-12 | The Toro Company | Mower deck with improved belt drive arrangement |
GB9200949D0 (en) | 1992-01-17 | 1992-03-11 | Medical Res Council | Diagnostic peptides |
FR2688227A1 (fr) | 1992-03-04 | 1993-09-10 | Inst Nat Sante Rech Med | Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques. |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
HUT70972A (en) | 1992-03-09 | 1995-11-28 | Ist Naz Stud Cura Dei Tumori | Protein compound capable of inhibiting tumoral growth |
AU4024593A (en) | 1992-04-14 | 1993-11-18 | Abbott Laboratories | Method of detecting tumors containing complexes of P53 and HSP70 |
ATE365209T1 (de) | 1992-05-14 | 2007-07-15 | Baylor College Medicine | Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
WO1994003599A1 (en) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
GB2270076A (en) | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
GB9223816D0 (en) | 1992-11-13 | 1993-01-06 | Medical Res Council | Heat shock proteins and the treatment of tumours |
NZ263550A (en) | 1993-03-19 | 1996-12-20 | Boehringer Ingelheim Int | Preparing cancer vaccines containing autologous tumour cells characterised in that tumour cells or firbroblasts are cultivated and transfected ex vivo with a composition of dna and a dna binding molecule conjugate |
US5496934A (en) | 1993-04-14 | 1996-03-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acids encoding a cellulose binding domain |
US6004941A (en) | 1993-06-14 | 1999-12-21 | Basf Aktiengesellschaft | Methods for regulating gene expression |
WO1995004824A1 (en) | 1993-08-05 | 1995-02-16 | Medvet Science Pty. Ltd. | Generation of dna libraries and retroviral vectors for same |
US5705159A (en) | 1993-08-31 | 1998-01-06 | John Wayne Cancer Institute | Immunoreactive peptide sequence from a 43 KD human cancer antigen |
US5750119A (en) | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
AU699405B2 (en) | 1994-07-08 | 1998-12-03 | Baxter International Inc. | Implanted device containing tumor cells for the treatment of cancer |
US5772995A (en) | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
CA2201587C (en) | 1994-10-03 | 2002-06-25 | Jeffrey Schlom | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
US6761892B1 (en) | 1995-08-18 | 2004-07-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US6331299B1 (en) | 1995-08-18 | 2001-12-18 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious disease and compositions useful in same |
AU6849396A (en) | 1995-08-18 | 1997-03-12 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious diseases and compositions useful in same |
US6719974B1 (en) | 1995-08-18 | 2004-04-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
CA2231998A1 (en) | 1995-09-13 | 1997-03-20 | Fordham University | Therapeutic and prophylactic methods using heat shock proteins |
US5985270A (en) | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
WO1997026910A2 (de) | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
DE19602985A1 (de) | 1996-01-27 | 1997-07-31 | Max Delbrueck Centrum | Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren |
EP0921816A4 (en) | 1996-03-28 | 2004-09-22 | Whitehead Biomedical Inst | CELLS WITH INCREASED OPSONINE CONTENT AND METHOD FOR REGULATING AN IMMUNE RESPONSE TO ANTIQUE |
US5747332A (en) | 1996-09-20 | 1998-05-05 | University Of New Mexico | Methods for purifying and synthesizing heat shock protein complexes |
US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
WO1998023735A1 (en) | 1996-11-26 | 1998-06-04 | Stressgen Biotechnologies Corp. | Immune responses using compositions containing stress proteins |
US5830464A (en) | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
ES2439014T3 (es) | 1998-02-20 | 2014-01-21 | The University Of Miami | Complejo de péptido antigénico-proteína de choque térmico modificada |
US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
US6797480B1 (en) | 1998-10-05 | 2004-09-28 | University Of Connecticut Health Center | Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents |
US6451316B1 (en) | 1998-10-05 | 2002-09-17 | University Of Conneticut Health Center | Methods for generating antigen-reactive T cells in vitro |
US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
US6734172B2 (en) * | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
CA2362126C (en) * | 1999-02-03 | 2017-01-17 | Amgen Inc. | B7rp-1 polypeptides |
CN101070540B (zh) * | 2000-04-28 | 2015-04-01 | 约翰霍普金斯大学 | 新的树突状细胞共刺激分子 |
US7132109B1 (en) | 2000-10-20 | 2006-11-07 | University Of Connecticut Health Center | Using heat shock proteins to increase immune response |
CA2452517A1 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
US7666581B2 (en) * | 2001-08-20 | 2010-02-23 | University Of Connecticut Health Center | Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease |
EP1434596B1 (en) * | 2001-10-09 | 2009-07-08 | Mayo Foundation For Medical Education And Research | Enhancement of immune responses by agonist 4-1bb-antibodies |
US20050019752A1 (en) | 2001-11-16 | 2005-01-27 | Genoveffa Franchini | Novel chimeric rev, tat, and nef antigens |
AU2003202908A1 (en) * | 2002-01-03 | 2003-07-24 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
US20030170756A1 (en) | 2002-02-01 | 2003-09-11 | Thomas Jefferson University | Treatment of tumor cells for use in immunotherapy of cancer |
CN1440812A (zh) * | 2002-02-27 | 2003-09-10 | 上海中信国健药业有限公司 | 一种使用cd137结合激动剂增强免疫应答的方法 |
AU2003217854A1 (en) * | 2002-02-28 | 2003-09-09 | Antigenics Inc. | Methods and products based on oligomerization of stress proteins |
IL164376A0 (en) * | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
US6984389B2 (en) * | 2002-04-25 | 2006-01-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
AU2003231098A1 (en) * | 2002-04-25 | 2003-11-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
DE60317677T2 (de) * | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
CA2501744C (en) | 2002-10-09 | 2012-01-03 | Central Iowa Health System | Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
JP2007505147A (ja) * | 2003-09-12 | 2007-03-08 | アンティジェニクス インコーポレーテッド | 単純ヘルペスウイルス感染の治療および予防用ワクチン |
AU2004276522B2 (en) | 2003-09-26 | 2010-12-02 | Merck Serono Sa | Leader sequences for use in production of proteins |
AU2004275814A1 (en) | 2003-09-26 | 2005-04-07 | University Of Miami | Tumor vaccine |
EP1720905A2 (en) * | 2003-12-11 | 2006-11-15 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
FR2867982B1 (fr) | 2004-03-26 | 2007-07-20 | Jean Marie Andrieu | Procede pour amplifier l'activite de vaccins therapeutiques |
WO2005124346A1 (en) * | 2004-05-17 | 2005-12-29 | The Board Of Trustees Of The University Of Illinois | 4-1bb receptors are expressed on regulatory t-cells |
CA2597511A1 (en) | 2005-02-24 | 2006-11-23 | Medical Research Council | Hivcon: an hiv immunogen and uses thereof |
AU2006244497B2 (en) * | 2005-05-06 | 2011-09-22 | Providence Health & Services - Oregon | Trimeric OX40L-immunoglobulin fusion protein and methods of use |
DK1919954T3 (en) * | 2005-08-30 | 2017-01-30 | Univ Miami | Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins |
MX2008013993A (es) * | 2006-05-03 | 2009-05-11 | Univ Colorado | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. |
WO2008108808A2 (en) * | 2006-08-24 | 2008-09-12 | Trustees Of Boston University | Complexes derived from heterohybrid cells and uses thereof |
EP2141997B1 (en) * | 2007-03-30 | 2012-10-31 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
ITPD20070252A1 (it) * | 2007-07-24 | 2009-01-25 | Primiero Paolo | Complessi di grp94 ed immunoglobuline g umane |
US9408909B2 (en) * | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
GB0719509D0 (en) * | 2007-10-05 | 2007-11-14 | Isis Innovation | Molecular adjuvant |
CN102014937A (zh) * | 2008-03-03 | 2011-04-13 | 迈阿密大学 | 基于异基因癌细胞的免疫治疗 |
EP2262531A1 (en) | 2008-03-08 | 2010-12-22 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
EP2274001A4 (en) | 2008-03-20 | 2012-08-01 | Univ Miami | GP96 THERMAL IMPACT PROTEIN VACCINATION AND METHODS OF USE |
US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
AU2009316371B2 (en) | 2008-11-21 | 2014-02-20 | University Of Miami | HIV/SIV vaccines for the generation of mucosal and systemic immunity |
MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
RU2015117604A (ru) * | 2009-04-03 | 2015-10-27 | Эйдженус Инк. | Способы получения и применения мультишаперон-антигенных комплексов |
ES2666152T3 (es) * | 2009-08-13 | 2018-05-03 | The Johns Hopkins University | Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR |
US9459246B2 (en) | 2009-09-08 | 2016-10-04 | Nodality, Inc. | Induced intercellular communication |
EP3375791A1 (en) * | 2009-09-30 | 2018-09-19 | Memorial Sloan Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
JP2013527753A (ja) * | 2010-03-23 | 2013-07-04 | イントレキソン コーポレーション | 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用 |
US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
WO2011146395A2 (en) * | 2010-05-17 | 2011-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade |
EP2571522A4 (en) * | 2010-05-21 | 2013-11-20 | Univ Miami | ANTICANCER TREATMENT |
US9234042B2 (en) * | 2010-10-18 | 2016-01-12 | Delphi Genetics Sa | Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein |
CN102462841A (zh) * | 2010-11-09 | 2012-05-23 | 中国科学院微生物研究所 | 一种促进gp96蛋白的免疫活性的方法及其应用 |
WO2012116142A2 (en) * | 2011-02-23 | 2012-08-30 | University Of Miami | Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv |
EP2714081A4 (en) | 2011-05-27 | 2015-09-09 | Cytocure Llc | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT |
AU2012351347B2 (en) * | 2011-12-12 | 2016-05-19 | Baylor College Of Medicine | Process of expanding T cells |
CN104203271B (zh) * | 2012-02-14 | 2017-08-25 | 梅里亚股份有限公司 | 表达狂犬病病毒和ox40蛋白的重组痘病毒载体及从其制造的疫苗 |
EP2925350B1 (en) * | 2012-12-03 | 2019-01-30 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
TR201815254T4 (tr) * | 2013-01-02 | 2018-11-21 | Glenmark Pharmaceuticals Sa | Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari |
KR20210041631A (ko) * | 2013-01-09 | 2021-04-15 | 유니버시티 오브 마이애미 | TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법 |
WO2014121099A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
CA2906356A1 (en) | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Antibodies to mica and micb proteins |
WO2014140884A2 (en) | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Methods and devices for removal of immunosuppressive ligands |
US10196435B2 (en) * | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
CN106029889A (zh) * | 2013-11-22 | 2016-10-12 | 德那翠丝有限公司 | 表达免疫细胞刺激受体激动剂的腺病毒 |
KR20230076867A (ko) * | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
WO2015131176A1 (en) * | 2014-02-28 | 2015-09-03 | Podack Eckhard R | Compositions, methods, and kits for treatment of cancer |
RU2689162C2 (ru) * | 2014-04-03 | 2019-05-24 | Огаста Юниверсити Рисерч Инститьют, Инк. | Способы повышения эффективности противоопухолевого иммунного ответа |
US9718870B2 (en) * | 2014-05-29 | 2017-08-01 | Medimmune, Llc | OX40L fusion proteins and uses thereof |
MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
MA41460A (fr) * | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
BR112017016681A2 (pt) * | 2015-02-06 | 2018-04-10 | Heat Biologics Inc | vetor de coexpressão de vacina e moléculas coestimulatórias |
CN115109158A (zh) * | 2015-05-07 | 2022-09-27 | 阿吉纳斯公司 | 抗ox40抗体及其使用方法 |
RU2746314C2 (ru) * | 2016-06-09 | 2021-04-12 | Пеликан Терапьютикс, Инк. | Антитела анти-tnfrsf25 |
WO2018187260A1 (en) * | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
CA3083481A1 (en) * | 2017-11-27 | 2019-05-31 | Heat Biologics, Inc. | Gp96-based cancer therapy |
EP3860647A4 (en) * | 2018-10-01 | 2022-10-19 | Heat Biologics, Inc. | CELL-BASED POLYTHERAPIES |
CN113646328B (zh) * | 2019-08-19 | 2024-03-26 | 南通壹宸生物医药科技有限公司 | 一种免疫细胞因子及其制备与用途 |
WO2021178416A1 (en) * | 2020-03-02 | 2021-09-10 | Heat Biologics, Inc. | Immune-mediated coronavirus treatments |
-
2016
- 2016-02-05 BR BR112017016681A patent/BR112017016681A2/pt not_active Application Discontinuation
- 2016-02-05 MX MX2017010159A patent/MX2017010159A/es unknown
- 2016-02-05 US US15/016,375 patent/US10046047B2/en active Active
- 2016-02-05 WO PCT/US2016/016682 patent/WO2016127015A1/en active Application Filing
- 2016-02-05 JP JP2017539659A patent/JP6744318B2/ja not_active Expired - Fee Related
- 2016-02-05 CN CN201680009177.5A patent/CN107208099B/zh active Active
- 2016-02-05 DK DK16747310.7T patent/DK3253876T3/da active
- 2016-02-05 ES ES16747310T patent/ES2845727T3/es active Active
- 2016-02-05 EP EP16747310.7A patent/EP3253876B1/en active Active
- 2016-02-05 RU RU2017127025A patent/RU2714157C2/ru active
- 2016-02-05 CA CA2975191A patent/CA2975191C/en active Active
- 2016-02-05 SG SG11201705844SA patent/SG11201705844SA/en unknown
- 2016-02-05 AU AU2016215175A patent/AU2016215175B2/en active Active
- 2016-02-05 KR KR1020177022218A patent/KR20170109582A/ko not_active Application Discontinuation
-
2017
- 2017-07-11 IL IL253423A patent/IL253423B/en unknown
-
2018
- 2018-06-04 HK HK18107290.2A patent/HK1247960A1/zh unknown
- 2018-06-25 US US16/016,771 patent/US10758611B2/en active Active
- 2018-06-25 US US16/016,770 patent/US10780161B2/en active Active
-
2020
- 2020-07-24 US US16/937,766 patent/US20210000945A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2017127025A3 (es) | 2019-07-17 |
ES2845727T3 (es) | 2021-07-27 |
US20180360955A1 (en) | 2018-12-20 |
AU2016215175B2 (en) | 2021-09-16 |
BR112017016681A2 (pt) | 2018-04-10 |
US10758611B2 (en) | 2020-09-01 |
JP2018509888A (ja) | 2018-04-12 |
SG11201705844SA (en) | 2017-08-30 |
US20210000945A1 (en) | 2021-01-07 |
RU2714157C2 (ru) | 2020-02-12 |
EP3253876A1 (en) | 2017-12-13 |
CA2975191C (en) | 2023-05-09 |
AU2016215175A1 (en) | 2017-09-21 |
IL253423A0 (en) | 2017-09-28 |
IL253423B (en) | 2021-08-31 |
HK1247960A1 (zh) | 2018-10-05 |
EP3253876B1 (en) | 2020-11-04 |
CN107208099B (zh) | 2022-05-13 |
JP6744318B2 (ja) | 2020-08-26 |
WO2016127015A1 (en) | 2016-08-11 |
DK3253876T3 (da) | 2021-01-25 |
US10780161B2 (en) | 2020-09-22 |
US20160250322A1 (en) | 2016-09-01 |
EP3253876A4 (en) | 2018-09-19 |
CN107208099A (zh) | 2017-09-26 |
KR20170109582A (ko) | 2017-09-29 |
CA2975191A1 (en) | 2016-08-11 |
RU2017127025A (ru) | 2019-03-07 |
US20190000967A1 (en) | 2019-01-03 |
US10046047B2 (en) | 2018-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017010159A (es) | Vector que expresa conjuntamente vacunas y moléculas coestimuladoras. | |
MX2022003698A (es) | Composiciones de nanoparticulas y metodos para inmunoterapia. | |
MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
PH12017500803A1 (en) | Anti-pd-1 antibodies | |
AU2016264323A8 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
MX2023002858A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
PH12017500441A1 (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions | |
MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
EA201891874A2 (ru) | Новые пептиды, комбинации пептидов и каркасы для применения в иммунотерапевтическом методе лечения различных видов рака | |
WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
MX2021001098A (es) | Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares. | |
MX2020010991A (es) | Composicion para la estimulacion ovarica controlada. | |
WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
CL2018002493A1 (es) | Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer. (divisional solicitud 201600227) | |
EA201792531A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака | |
MX2022003704A (es) | Anticuerpos anti-huntingtina (htt) derivados de humano y usos de los mismos. | |
MY191539A (en) | Streptococcal vaccine | |
AR092737A1 (es) | Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf, uso y metodo de tratamiento del cancer | |
MX2021013109A (es) | Proceso de preparacion de una vacuna tetravalente atenuada contra el virus del dengue. | |
MX2015017959A (es) | Composiciones y metodos para inmunoterapia. | |
GB201017519D0 (en) | Vaccines | |
MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
MX358507B (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c. | |
AU2015300258A8 (en) | CDCA1-derived peptide and vaccine containing same | |
MX2021015026A (es) | Peptido derivado de urlc10 y vacuna que lo contiene. |